全、新、优、品、好四大特点：

磷酸化帕金蛋白抗体费用 全：公司提供上万种产品，涵盖了生物试剂，elisa试剂盒，标准品，培养基，原装耗材，抗体、培养基、ATCC细胞等，基本上各种科研所需产品在我司都能找到。

新：产品更新速度较快，基本上每周都有新产品出现。

优：产品质量好，投诉比较少。

好：我公司具有优质的技术团队，产品一旦售出，实验过程中遇到困难可提供在线技术咨询。使您使用产品时没有任何的后顾之忧。

磷酸化帕金蛋白抗体费用 英文名称  Anti-phospho-PARK2(Ser378)

中文名称  磷酸化帕金蛋白抗体费用 

别    名 PARK2(phospho S378); AR JP; E3 ubiquitin protein ligase parkin; FRA6E; LPRS 2; LPRS2; PARK 2; PARK2; Parkinson disease (autosomal recessive juvenile) 2; Parkinson disease protein 2; Parkinson juvenile disease protein 2; PDJ; PRKN 2; PRKN; PRKN2; Ubiquitin E3 ligase PRKN.

产品属性：

浓    度  1mg/1ml

规 格  0.1ml/100μg

抗体来源  Rabbit

克隆类型   polyclonal

交叉反应   Human, Pig, Guinea Pig

产品类型   一抗 磷酸化抗体  

研究领域    免疫学 神经生物学

蛋白分子量  predicted molecular weight: 51kDa 

性    状   Lyophilized or Liquid

免 疫 原  KLH conjugated Synthesised phosphopeptide derived from human PARK2 around the phosphorylation site of Ser378

亚    型  IgG

纯化方法   affinity purified by Protein A

储 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化帕金蛋白抗体费用 产品应用   WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蜡切片需做抗原修复） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

产品介绍 Parkinson's Disease, the second most common neurodegenerative disease after Alzheimer's Disease, is characterized by the loss of dopaminergic neurons and the presence of Lewy bodies (comprised of alpha synuclein and parkin inclusions). Autosomal Recessive Juvenile Parkinsonism (AR-JP) is a recently described form of Parkinson's Disease that has been linked to a gene that codes for parkin. Parkin, a 52 kDa protein, has a suggested role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome.

Function : Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene.

Subunit : Forms an E3 ubiquitin ligase complex with UBE2L3 or UBE2L6. Mediates 'Lys-63'-linked polyubiquitination by associating with UBE2V1. Part of a SCF-like complex, consisting of PARK2, CUL1 and FBXW7. Interacts with SNCAIP. Binds to the C2A and C2B domains of SYT11. Interacts and regulates the turnover of SEPT5. Part of a complex, including STUB1, HSP70 and GPR37. The amount of STUB1 in the complex increases during ER stress. STUB1 promotes the dissociation of HSP70 from PARK2 and GPR37, thus facilitating PARK2-mediated GPR37 ubiquitination. HSP70 transiently associates with unfolded GPR37 and inhibits the E3 activity of PARK2, whereas, STUB1 enhances the E3 activity of PARK2 through promotion of dissociation of HSP70 from PARK2-GPR37 complexes. Interacts with PSMD4 and PACRG. Interacts with LRRK2. Interacts with RANBP2. Interacts with SUMO1 but not SUMO2, which promotes nuclear localization and autoubiquitination. Interacts (via first RING-type domain) with AIMP2 (via N-terminus). Interacts with PSMA7 and RNF41. Interacts with PINK1.

Subcellular Location : Cytoplasm, cytosol. Nucleus. Endoplasmic reticulum. Mitochondrion. Note=Mainly localizes in the cytosol. Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Relocates to dysfunctional mitochondria that have lost the mitochondrial membrane potential; recruitment to mitochondria is PINK1-dependent.

Post-translational modifications : Auto-ubiquitinates in an E2-dependent manner leading to its own degradation. Also polyubiquitinated by RNF41 for proteasomal degradation.

S-nitrosylated. The inhibition of PARK2 ubiquitin E3 ligase activity by S-nitrosylation could contribute to the degenerative process in PD by impairing the ubiquitination of PARK2 substrates.

DISEASE : Defects in PARK2 are a cause of Parkinson disease (PARK) [MIM:168600]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

Defects in PARK2 are the cause of Parkinson disease type 2 (PARK2) [MIM:600116]; also known as early-onset parkinsonism with diurnal fluctuation (EPDF) or autosomal recessive juvenile Parkinson disease (PDJ). A neurodegenerative disorder characterized by bradykinesia, rigidity, postural instability, tremor, and onset usually befor 40. It differs from classic Parkinson disease by early DOPA-induced dyskinesia, diurnal fluctuation of the symptoms, sleep benefit, dystonia and hyper-reflexia. Dementia is absent. Pathologically, patients show loss of dopaminergic neurons in the substantia nigra, similar to that seen in Parkinson disease; however, Lewy bodies (intraneuronal accumulations of aggregated proteins) are absent.

Similarity : Belongs to the RBR family. Parkin subfamily.

Contains 1 IBR-type zinc finger.

Contains 2 RING-type zinc fingers.

Contains 1 ubiquitin-like domain.

Database links : UniProtKB/Swiss-Prot: O60260.2

parkin基因的突变，患者很早就会出现氏症的，Parkin属于RBR蛋白家族，与泛素相关蛋白分解途径有关.

实验流程：

正在热销的相关产品：

Human 11-dehydro-thromboxane B2,11-DH-TXB2 ELISA Kit 人11去氢烷B2Multi-class antibodies规格： 48T

Anti-Resistin (human, dog) 抵抗素抗体(人，犬)Multi-class antibodies规格： 0.1ml

Rhesus antibody Rh GZMA/Granzyme A 颗粒酶A抗体 规格 0.2ml

SP-A(Human Pulmonary surfatcant-associated protein A) ELISA Kit 人肺表面活性物质相关蛋白A 96T

Optimedin 英文名称： 嗅球蛋白3抗体 0.2ml

BRD7 英文名称： 相关转录调节蛋白抗体 0.2ml

Anti-Resistin (human, dog) 抵抗素抗体(人，犬)Multi-class antibodies规格： 0.1ml

Anti-HIV gp41/FITC 荧光素标记病毒抗体IgGMulti-class antibodies规格： 0.2ml

Phospho-PAK4 (Ser474)/PAK5 (Ser602)/PAK6 (Ser560) /FITC 荧光素标记磷酸化p21激活激酶4、5、6抗体IgGMulti-class antibodies规格： 0.2ml

Rhesus antibody Rh ATG9A 自噬相关蛋白9A抗体 规格 0.2ml

Amylin 相关肽(胰岛淀粉样肽) 0.5mg

GABA A Receptor gamma 2 英文名称： γ基γ2受体/GABAA Rγ2抗体 0.1ml

Rhesus antibody Rh Rabbit Anti-mouse IgM/Alexa Fluor 647 Alexa Fluor 647标记的兔抗小鼠IgM 规格 0.1ml

Phospho-PAK4 (Ser474)/PAK5 (Ser602)/PAK6 (Ser560) /FITC 荧光素标记磷酸化p21激活激酶4、5、6抗体IgGMulti-class antibodies规格： 0.2ml

Osteocalcin 小鼠骨钙素Multi-class antibodies规格： 48T

Anti-Apo B 载脂蛋白B抗体Multi-class antibodies规格： 0.1ml

Rhesus antibody Rh Mouse Anti-rat IgG/Bio 生物素标记的小鼠抗大鼠IgG 规格 0.1ml

APCR(Human activated protein C resistance) ELISA Kit 人活化蛋白C抵抗素 96T

SLAP 英文名称： SLAP蛋白抗体 0.1ml

C6orf192 英文名称： 8号染色体开放阅读框192抗体 0.2ml

Anti-Apo B 载脂蛋白B抗体Multi-class antibodies规格： 0.1ml

cycloheximide

DG-18琼脂 DICHLORANGLYCEROL (DG-18) AGAR 用于食品中和酵母菌分离培养

糖发酵基础肉汤 Bromcersol Purple Broth Base 250克 微生物检验中各种糖发酵实验，无菌加入各种糖醇类物质

支原体肉汤基础250g/瓶含酚红，用于支原体的培养，使用前添加20%小牛血清及抑菌剂incubationmedia支原体肉汤基础250g/瓶含酚红，用于支原体的培养，使用前添加20%小牛血清及抑菌剂

theSmallestBrothMedium

TerrificBrothHCM00g用于提高大肠杆菌中质粒DNA的成品得率Terrificbrothisusedwithglycerolincultivatingrec...

麦康凯琼脂 (CM0007) Oxoid incubation media 麦康凯琼脂 (CM0007) Oxoid

灭酵母 食用酵母、产酒精。 支/瓶

TSIAgar

支原体检测培养基

磷酸化帕金蛋白抗体费用 Bolton肉汤基础  规格：  250g  用途：  用于空肠弯曲菌的选择性增菌(GB)，每100mL基础培养基需添加1支配套试剂(SR0340)

哥伦比亚琼脂培养基  规格：  250g  用途：  灭菌后冷至45℃左右时加入5%脱纤维羊血，用于空肠弯曲菌的培养。(CP、GB、EP、USP)

脑—心浸萃液态培养基  规格：  100g  用途：  广泛用于霉菌、酵母、细菌的培养，包括营养要求较高的微生物的培养，特别用于饮用天然矿泉水和城...

四酸亮绿增菌液  规格：  2X5支  用途：  含液2ml/支和煌绿1ml/支，2支添加于100mL（023031）中配成TTB

技术外包服务:

★磷酸化帕金蛋白抗体费用 分子生物学：质粒抽提、PCR、Q-PCR、RT-PCR、分子生物学：基因合成、引物合成、基因测序、载体构建等

★蛋白工程：原核、哺乳动物蛋白表达系统等

★病毒包装：腺病毒、慢病毒等

★抗体工程：磁珠分选、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★细胞工程：细胞表型分析(凋亡、增殖、周期、迁移、侵袭、修复、克隆形成)、细胞培养、细胞膜制备、稳定细胞株构建、细胞RNAi技术等等。